Novo Nordisk (NVO)
(Delayed Data from NYSE)
$128.64 USD
+3.38 (2.70%)
Updated Apr 23, 2024 03:59 PM ET
After-Market: $128.80 +0.16 (0.12%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Price, Consensus and EPS Surprise
NVO 128.64 +3.38(2.70%)
Will NVO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for NVO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NVO
Novo Nordisk (NVO) Boasts Earnings & Price Momentum: Should You Buy?
Novo Nordisk (NVO) Boasts Earnings & Price Momentum: Should You Buy?
NVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies
Novo Nordisk (NVO) Stock Falls Amid Market Uptick: What Investors Need to Know
The Zacks Analyst Blog Highlights Microsoft, Novo Nordisk, United Parcel Service, Booking and Elevance Health
Other News for NVO
3 Potential Biopharma Buyout Targets
TikTok to restrict weight loss drug promotion
3 Stocks With the Potential to Surpass Analyst Expectations for 2024
PPH: Buy The Pullback In This Big Pharma ETF For Long-Term Total Returns
TikTok to restrict weight loss drug promotion (updated)